Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Accendra Health Inc filings on SEC EDGAR ↗
Accendra Health reported a net loss of $19.7 million for the third quarter of 2026, a significant improvement from the $150.3 million loss in the prior year period. Total net revenue declined to $601.8 million from $697.3 million, while the company's total deficit increased to $568.2 million as of September 30, 2026.
Accendra Health reported a disappointing Q3 2026, missing expectations and lowering full-year guidance due to operational friction, share loss in key categories, and a major commercial payer contract termination.
Accendra Health reported third quarter 2026 net revenue of $601.8 million and a GAAP net loss from continuing operations of $18.0 million. CEO Kenny Gardner-Smith noted that 2026 results have fallen short of expectations and announced the development of a value creation plan to return the business to profitability.
Term
Q3 2026
“It is equally clear to me that our results to date in 2026 have fallen well short of our expectations and potential. We have identified four key areas which are critical to our continued transformation and returning the business to the kind of profitability that our shareholders should expect”
Kenny Gardner-Smith, President & Chief Executive Officer
“We are already taking action on our turnaround, and, over the next several months, we will have our value creation plan fully underway. The value creation plan is the cornerstone of returning the business to its potential, and we look forward to sharing details with all stakeholders in the coming months”
Kenny Gardner-Smith, President & Chief Executive Officer
Perry A. Bernocchi will step down as Executive Vice President and Chief Operating Officer of Accendra Health, effective October 29, 2026. He will transition to a role as Strategic Advisor to the CEO through December 31, 2026, maintaining his current base salary and 2026 bonus eligibility during the transition period.
Accendra Health $150M Debt Financing with PNC Bank, National Association
Accendra Health's subsidiaries entered into an amendment to their Receivables Purchase Agreement with PNC Bank, extending the $150 million facility's termination date to October 2029. The amendment also revises account control provisions and reporting obligations while maintaining the existing facility size to ensure liquidity. The program is backed by the company's accounts receivable portfolio through its Accendra Funding and Byram Healthcare units.
Accendra Health received a deficiency notice from the NYSE for failing to maintain an average market capitalization and stockholders' equity of at least $50.0 million. The company has 45 days to submit a business plan to regain compliance within 18 months and its stock will continue to trade on the exchange during this period.
Accendra Health received a deficiency notice from the NYSE on October 6, 2026, because its common stock average closing price fell below $1.00 over a 30 trading-day period. The company has six months to regain compliance and is considering alternatives including a potential reverse stock split. The notice does not immediately impact the listing or the company's business operations.
Accendra Health announced that Kenneth Gardner-Smith will assume the role of President and CEO on October 5, 2026, succeeding Edward A. Pesicka. Mr. Pesicka will retire from the Board and enter into a 30-month consulting agreement to ensure a smooth transition, during which his existing equity awards will continue to vest.
Accendra Health has appointed Kenneth Gardner-Smith as its next President and CEO, succeeding the retiring Edward A. Pesicka in early Q4 2026. The company entered into an offer letter with Mr. Gardner-Smith providing for a $1,000,000 base salary, a $650,000 sign-on bonus, and an annual long-term incentive target of $6,000,000. He has served on the company's board since 2022 and previously held senior leadership roles at Veritas Veterinary Partners and DaVita.